Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2012, vol. 21, nr 2, March-April, p. 201–205

Publication type: original article

Language: English

Second-Trimester IL-15 and IL-18 Levels in the Amniotic Fluid of Fetuses with Normal Karyotypes and with Chromosome Abnormalities

Stężenie IL-15 i IL-18 w płynie owodniowym w drugim trymestrze ciąży u płodów z prawidłowym kariotypem i aberracjami chromosomowymi

Dominika Klimkiewicz-Blok1,, Jerzy Florjański1,, Jerzy Zalewski2,, Radosław Blok3,

1 Second Department of Gynecology, Obstetrics and Neonatology, Wroclaw Medical University, Wrocław, Poland

2 Department of Gynecology and Obstetrics, Division of Public Health, Wroclaw Medical University, Wrocław, Poland

3 First Department of Gynecology and Obstetrics, Wroclaw Medical University, Wrocław, Poland

Abstract

Background. Little is known about the behavior of interleukin 15 (IL-15) and 18 (IL-18) in the amniotic fluid in the second trimester of gestations complicated by chromosomal defects in the fetus. Likewise, it has not yet been established whether a fetus with chromosome abnormalities creates its immunity mechanisms in the same way as a fetus with a normal karyotype.
Objectives. The aim of this work was to assess the concentration of IL-15 and IL-18 in the amniotic fluid in the second trimester of gestation in fetuses with normal karyotypes and with chromosome abnormalities.
Material and Methods. The material consisted of 51 samples of amniotic fluid obtained from genetic amniocenteses carried out between the 15th and the 19th weeks of gestation. On the basis of cytogenetic screening, two groups were singled out: Group I – 45 fetuses with normal karyotypes, and Group II – 6 fetuses with abnormal karyotypes. The concentrations of IL-15 and IL-18 in the amniotic fluid were assessed with ready-made assays and analyzed, and the results from both groups were compared.
Results. The differences between the IL-15 levels in the amniotic fluid from Groups I and II proved to be statistically insignificant (p = 0.054). However, the average IL-18 levels in the amniotic fluid of the fetuses with normal karyotypes were significantly higher than in the amniotic fluid of the fetuses with chromosome abnormalities (p = 0.032).
Conclusion. Some defense mechanisms in the second trimester of gestation in fetuses with chromosome abnormalities may develop in a different way than in fetuses with normal karyotypes.

Streszczenie

Wprowadzenie. Niewiele wiadomo o zachowaniu się interleukiny 15 (IL-15) i 18 (IL-18) w płynie owodniowym w II trymestrze ciąż powikłanych aberracjami chromosomowymi u płodu. Do tej pory nie rozstrzygnięto także, czy u płodów z aberracjami chromosomowymi tworzenie mechanizmów odporności przebiega tak samo jak u płodów z prawidłowym kariotypem.
Cel pracy. Ocena stężenia IL-15 i IL-18 w płynie owodniowym w II trymestrze ciąży u płodów z prawidłowym kariotypem i aberracjami chromosomowymi.
Materiał i metody. Materiał obejmował 51 próbek płynu owodniowego uzyskanego na drodze amniocentez genetycznych wykonywanych między 15. a 19. tygodniem ciąży. Na podstawie badania cytogenetycznego wyodrębniono dwie grupy: grupa I – 45 płodów z prawidłowym kariotypem i grupa II – 6 płodów z nieprawidłowym kariotypem. Stężenia IL-15 i IL-18 w płynie owodniowym oznaczono za pomocą gotowych testów, a uzyskane z obu grup wyniki porównano.
Wyniki. Różnice między stężeniami IL-15 w płynie owodniowym w grupach I i II okazały się nieistotne statystycznie (p = 0,054). Średnie stężenia IL-18 w płynie owodniowym były znamiennie większe u płodów z prawidłowym kariotypem niż u płodów z aberracjami chromosomowymi (p = 0,032).
Wnioski. Niektóre mechanizmy obronne w II trymestrze ciąży u płodów z aberracjami chromosomowymi mogą rozwijać się odmiennie niż u płodów z prawidłowym kariotypem.

Key words

interleukin 15, interleukin 18, amniotic fluid, chromosome aberration

Słowa kluczowe

interleukina 15, interleukina 18, płyn owodniowy, aberracje chromosomowe

References (30)

  1. del Carmen Saucedo M, DeVigan C, Vodovar V, Lelong N, Goffinet F, Khoshnood B: Measurement of nuchal translucency and the prenatal diagnosis of Down Syndrome. Obstet Gynecol 2009, 114(4), 829–838.
  2. Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH: Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 2009, 33(3), 259–264.
  3. Has R, Kalelioglu I, Yuksel A, Ibrahimoglu L, Ermis H, Yildirim A: Fetal nasal bone assessment in first trimester down syndrome screening. Fetal Diagn Ther 2008, 24(1), 61–66.
  4. Sieroszewki P, Baś-Budecka E, Perenc M: Nasal bone (NB) length measurement in the first trimester of pregnancy in Polish population and its validity as fetal aneuploidy indicator. Ginekol Pol 2007, 78(8), 616–620.
  5. Borenstein M, Persico N, Kagan KO, Gazzoni A, Nicolaides KH: Frontomaxillary facial angle in screening for trisomy 21 at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol 2008, 32 (1), 5–11.
  6. Sacchini C, El-Sheikhah A, Cicero S, Rembouskos G, Nicolaides KH: Ear length in trisomy 21 fetuses at 11–14 weeks of gestation. Ultrasound Obstet Gynecol 2003, 22(5), 460–463.
  7. Gollo CA Murta CG, Bussamra LC, Santana RM, Moron AF: Predictive value for fetal outcome of Doppler velocimetry of the ductus venosus between the 11th and 14th gestation week. Rev Bras Ginecol Obstet 2008, 30(1), 5–11
  8. Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH: Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 2009, 33(5), 512–517.
  9. Goetzl L, Krantz D, Simpson JL, Silver RK, Zachary JM, Perganent E, Platt LD, Mahoney MJ, Wapner RJ: Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 2004, 104, 30–36.
  10. Yaron Y, Ochshorn Y, Tsabari S, Shira AB: First-trimester nuchal translucency and maternal serum free betahCG and PAPP-A can detect triploidy and determine the parental origin. Prenat Diagn 2004, 24, 445–450.
  11. Agarwal R, Loganath A, Roy AC, Wong YC, Ng SC: Expression profiles of interleukin-15 in early and late gestational human placenta and in pre-eclamptic placenta. Molecular Hum Reprod 2001, 7, 97–101.
  12. Lin SJ, Chao HCh, Kuo ML: The effect of interleukin 12 and interleukin 15 on CD69 expression of T-lymphocytes and natural killer cells from umbilical cord blood. Biol Neonate 2000, 78, 181–185.
  13. Choi SS, Chhabra VS, Nguyen QH, Ank BJ, Stiehm ER, Roberts RL: Interleukin-15 enhances cytotoxicity, receptor expression and expansion of neonatal natural killer cells in long-term culture. Clin Diag Lab Immunol 2004, 9, 879–888.
  14. Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Todsato G: Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997, 7, 231–237.
  15. Bulfone-Paus S, Ungureanu D, Pohl T, Lindner G, Paus R, Ruckert R, Krause H, Kunzendorf U: Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 1997, 10, 1124–1128.
  16. Fortunato SJ, Menon R, Lombardi SJ: IL-15, a novel cytokine produced by human fetal membranes, is elevated in preterm labor. AJRI 1998, 39, 16–23.
  17. Heikkinen J, Mottonen M, Pulkki K, Lassila O, Alanen A: Cytokine levels in midtrimester amniotic fluid in normal pregnancy in the prediction of pre-eclampsia. Scand J Immunol 2001, 53, 310–314.
  18. Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K: Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 1998, 10, 259–264.
  19. Stoll S, Muller G, Kurimoto M, Saloga J, Tanimoto T, Yamauchi H, Okamura H, Knop J, Enk AH: Production of IL-18 /IFN-gamma-inducing factor/messenger RNA and functional protein by murine keratinocytes. J Immunol 1997, 159, 298–302.
  20. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT: Interleukin-18 / interferon gamma inducing factor / is produced by osteoblasts and acts via granulocytemacrophage colony stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 1997, 185, 1005–1012.
  21. Hoshino T, Wiltrout RH, Young HA: IL-18 is a potent coinducer of IL-13 in NK and T-cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999, 162, 5070–5077.
  22. Yoshimoto T, Mizutani H, Tsutsui H, Noben-Trauth N, Yamanaha K, Tanaka M, Izumi S, Okamura H, Paul WE: IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol 2000, 1, 132–137.
  23. Tokmadźić VS, Tsuji Y, Bogović T, Laskarin G, Cupuraija K, Strbo N, Koyama K, Okamura H, Podack ER, Rukarina D: IL-18 is present at the maternal-fetal interface and enhances cytotoxic activity of decidual lymphocytes. Am J Reprod Immunol 2002, 48, 191–200.
  24. Jacobsson B, Holst RM, Mattsby-Baltzer I, Nikolaitchouk N, Wennerholm UB, Hagberg H: Interleukin-18 in cervical mucus and amniotic fluid: relationship to microbial invasion of the amniotic fluid, intra-amniotic inflammation and preterm delivery. Int J Obstet Gynecol 2003, 110, 598–603.
  25. Menon R, Lombardii SJ, Fortunato SJ: Obstetrics: IL-18, a product of choriodecidual cells, increase during premature rupture of membranes but fails to turn on the Fas-FasLmediated apoptosis pathway. J Assist Reprod Gen 2001, 18, 276–280.
  26. Splichalova A, Trebichavsky I, Muneta Y, Mori Y, Splichal I: Effect of bacterial virulence on IL-18 expression in the amnion infected with Escherichia coli. Am J Reprod Immunol 2005, 53, 255–260.
  27. Wallace EM, D’Antona D, Shearing C, Evans LW, Thirunavukarasu P, Ashby JP, Shade M, Groome NP: Amniotic fluid levels of dimeric inhibins, pro-alpha C inhibin, activin A and follistatin in Down’s syndrome. Clin Endocrinol (Oxf) 1999, 50, 669–673.
  28. Wallace EM, Crossley A, Groome NP, Aitken DA: Amniotic fluid inhibin-A in chromosomally normal and Down’s syndrome pregnancies. J Endocrinol 1997, 152, 109–112.
  29. Shohat B, Shohat M., Faktor JH, Barkay G, Haren D, Kozenitzky L: Soluble interleukin-2 receptor and interleukin2 in human amniotic fluid of normal and abnormal pregnancies. Biol Neonate 1993, 63, 281–284.
  30. Bromage SJ, Lang AK, Atkinson I, Searle RF: Abnormal TGF beta levels in the amniotic fluid of Down syndrome pregnancies. Am J Reprod Immunol 2000, 44, 205–210.
© Wroclaw Medical University